A Phase 1, Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Belzutifan (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms MK-6482-018
- Sponsors Merck Sharp & Dohme
- 05 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2021 Status changed from not yet recruiting to recruiting.
- 11 May 2021 Planned initiation date changed from 21 May 2021 to 7 Jun 2021.